Clinical trial Recruiting at 1 site Observational Ages 45 and up

Understanding cognitive decline and mild cognitive impairment in Alzheimer's disease

Official title: AlfaCognition: Longitudinal Study for the Characterization of the Phases of Subjective Perception of Cognitive Decline and Mild Cognitive Impairment of Alzheimer's Disease.

Run by Barcelonabeta Brain Research Center, Pasqual Maragall Foundation · NCT03851523 · Data updated 2026-11-12

This study looks at how people with different levels of memory issues, including those with Alzheimer's, feel about their cognitive decline to better understand how it progresses.

More Alzheimer Disease trials

Quick facts

Study typeObservational
Ages45 Years and up
SexAll
Enrollment400 (estimated)
SponsorBarcelonabeta Brain Research Center, Pasqual Maragall Foundation
Academic / other
Locations1 site (Barcelona, Catalonia)
StatusRecruiting
StartedFebruary 12, 2018
Main results expectedDecember 31, 2026
Study endsDecember 31, 2027
Registry record updatedMay 31, 2025
Trial IDNCT03851523 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include men and women aged 45 to 74 with subjective cognitive decline, mild cognitive impairment, or mild dementia.

Probably not a fit

Patients with significant systemic illnesses or cognitive impairments unrelated to Alzheimer's disease may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to characterize the phases of subjective perception of cognitive decline and mild cognitive impairment associated with Alzheimer's disease. It involves assessing cognitively healthy individuals, those with subjective cognitive decline, mild cognitive impairment, and mild dementia. Participants will be evaluated through subjective memory complaints and clinical interviews, with the involvement of a relative to provide additional insights. The study seeks to enhance understanding of the progression of cognitive decline in Alzheimer's disease without any direct interventions.

Why it matters

Potential benefit: If successful, this study could improve early detection and understanding of cognitive decline in Alzheimer's disease, leading to better patient management.

How similar studies have gone: Other studies have shown success in understanding cognitive decline in Alzheimer's disease, making this approach relevant and potentially impactful.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Men and women between 45 and 74 years at the time of inclusion in the 45-65/FPM2012 study or older than 45 for persons who have not previously participated in 45-65/FPM2012.
2. Cognitively healthy persons with SCD, as well as people with MCI and mild dementia.
3. Participation of a relative to perform the subjective memory complaint and clinical interview.

Exclusion criteria:

1. Any significant systemic illness or unstable medical condition which could lead to difficulty complying with the protocol.
2. Any significant disorder that could course with cognitive impairment that is not related to AD.
3. Family history of monogenic AD.

Where it's running

  • Barcelonabeta Brain Research Center
    Barcelona, Catalonia, Spain
    Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.